OncoMatch/Clinical Trials/NCT06911502
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Is NCT06911502 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for follicular lymphoma.
Treatment: Golcadomide · Rituximab · Lenalidomide · Cyclophosphamide · Doxorubicin · Vincristine · Prednisone/Prednisolone · Bendamustine — The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymphoma who have received at least one line of prior systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-cd20 monoclonal antibody (rituximab, obinutuzumab)
Must have received: alkylating agent (cyclophosphamide, bendamustine)
Lab requirements
Blood counts
ANC ≥ 1,000 cells/mm3; PLT count ≥ 75,000 cells/mm3; Hb ≥ 7.5 g/dL
Kidney function
eGFR ≥ 30 ml/min/1.73m²
Liver function
AST/SGOT or ALT/SGPT ≤ 2.5 x ULN (≤ 5.0× ULN if liver involvement); serum total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN if liver involvement; ≤ 5.0 × ULN for Gilbert's syndrome)
Cardiac function
LVEF ≥ 45% for participants receiving anthracycline-based chemotherapy
Lab parameters: ANC ≥ 1,000 cells/mm3, PLT count ≥ 75,000 cells/mm3, Hb ≥ 7.5 g/dL; eGFR ≥ 30 ml/min/1.73m²; AST/SGOT or ALT/SGPT ≤ 2.5 x ULN (≤ 5.0× ULN if liver involvement); serum total bilirubin ≤ 1.5 × ULN (≤ 3.0 × ULN if liver involvement; ≤ 5.0 × ULN for Gilbert's syndrome); LVEF ≥ 45% for participants receiving anthracycline-based chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0225 · Birmingham, Alabama
- Infirmary Cancer Care · Mobile, Alabama
- Alaska Oncology and Hematology · Anchorage, Alaska
- Local Institution - 0215 · Little Rock, Arkansas
- City of Hope Comprehensive Cancer Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify